Bone Biologics Corp
BBLG Nasdaq· Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last close · Oct 23, 2026
$0.39
KIRA · Stoqly’s AI analyst, in plain words
- Bone Biologics Corp lost $3.1M in fiscal 2025.
Market cap
$0.7M
P/E
—
Revenue
—
Net income
−$3.1M
Free cash flow
—
Operating margin
—
Bone Biologics Corp in 30 seconds · fiscal 2025
Does it make a profit?
−$3.1M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Bone Biologics Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Bone Biologics Corp
- CIK
- 0001419554
Bone Biologics Corp · BBLG
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.0M | — | — |
| Net interest income | — | — | $0.0M | — | — |
| Operating margin | — | — | −496,226.3% | — | — |
| Net income | −$1.6M | −$1.5M | −$8.9M | −$4.1M | −$3.1M |
| Net margin | — | — | −470,984.2% | — | — |
| Diluted EPS | −$0.35 | −$31.15 | −$34.01 | −$28.96 | −$2.65 |
| Cash | |||||
| Cash from operations | −$1.2M | −$3.6M | −$9.6M | −$4.1M | −$2.7M |
| Share count change | 56.0% | −98.9% | 451.6% | −3.8% | 364.4% |
| Debt and strength | |||||
| Cash and short-term investments | $6.7M | $7.5M | $3.0M | $3.3M | $5.3M |
| Shareholders' equity | $6.6M | $5.9M | $2.9M | $3.5M | $5.4M |
| Current ratio | — | 3.3x | 4.5x | 10.2x | 13.8x |
| Returns and quality | |||||
| Return on equity | — | −23.7% | −202.1% | −128.7% | −70.2% |
| Return on tangible equity | −24.5% | −25.0% | −307.9% | −210.3% | −57.8% |
| Altman Z'' | — | −23.5 | −78.7 | −63.5 | −33.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bone Biologics Corp · BBLG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.39 a share, the company is worth $0.7M.
Source: SEC EDGAR XBRL filings (CIK 0001419554). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.